Media coverage about VIVUS (NASDAQ:VVUS) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. VIVUS earned a news impact score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.2885220873465 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Separately, ValuEngine upgraded VIVUS from a “hold” rating to a “buy” rating in a report on Monday, October 2nd.
Shares of VIVUS (VVUS) traded down $0.02 during mid-day trading on Wednesday, hitting $0.51. The stock had a trading volume of 799,300 shares, compared to its average volume of 724,361. The company has a quick ratio of 7.09, a current ratio of 7.47 and a debt-to-equity ratio of 643.86. The company has a market capitalization of $56.15, a PE ratio of 1.56 and a beta of 0.77. VIVUS has a 12 month low of $0.50 and a 12 month high of $1.38.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/12/20/vivus-vvus-receives-daily-media-sentiment-score-of-0-09.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.